Cannara Biotech (TSXV:LOVE) Cash-to-Debt

: 0.05 (As of Nov. 2023)

View and export this data going back to 2019. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cannara Biotech's cash to debt ratio for the quarter that ended in Nov. 2023 was 0.05.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Cannara Biotech couldn't pay off its debt using the cash in hand for the quarter that ended in Nov. 2023.

The historical rank and industry rank for Cannara Biotech's Cash-to-Debt or its related term are showing as below:

TSXV:LOVE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05 Med: 0.36 Max: No Debt
Current: 0.05

During the past 6 years, Cannara Biotech's highest Cash to Debt Ratio was No Debt. The lowest was 0.05. And the median was 0.36.

TSXV:LOVE's Cash-to-Debt is ranked worse than
91.02% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs TSXV:LOVE: 0.05

Cannara Biotech Cash-to-Debt Historical Data

The historical data trend for Cannara Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cannara Biotech Annual Data

Trend

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Cash-to-Debt

Get a 7-Day Free Trial

2.00

0.60

0.39

0.25

0.09

Cannara Biotech Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Cash-to-Debt	Get a 7-Day Free Trial															0.14	0.10	0.09	0.09	0.05

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannara Biotech Cash-to-Debt Distribution

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Cash-to-Debt falls into.

Cannara Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cannara Biotech's Cash to Debt Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.271	/	(6.045	+	39.739)
	=	0.09

Cannara Biotech's Cash to Debt Ratio for the quarter that ended in Nov. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.639	/	(8.721	+	39.933)
	=	0.05

Cannara Biotech (TSXV:LOVE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cannara Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech (TSXV:LOVE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

LOVFF:USA 8CB0:Germany

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .